Anti-RNase L In Vivo Antibody - Ultra Low Endotoxin
Introducing the Anti-RNase L In Vivo Antibody – Ultra Low Endotoxin from Assay Genie, a highly specific monoclonal antibody engineered for precise in vivo applications. This antibody targets the RNase L protein, which plays a pivotal role in antiviral defense and the regulation of cellular RNA stability, making it indispensable for research in virology, immunology, and related fields. Characterized by ultra-low endotoxin levels (<0.002 EU/µg), this antibody ensures minimal immune response interference, making it ideal for sensitive applications such as in vivo studies, ELISA, western blot, immunoprecipitation, and immunofluorescence.
Available in convenient sizes, it is formulated in phosphate-buffered saline to maintain stability and efficacy. RNase L is an endoribonuclease found in many cell types and is activated by 2-5A synthetic oligoadenylates during viral infections, leading to the degradation of RNA and inhibition of protein synthesis. This crucial enzyme is part of the interferon-regulated 2-5A system, instrumental in the body's antiviral mechanisms. Enhance your research with the reliability and versatility of the Anti-RNase L In Vivo Antibody – Ultra Low Endotoxin from Assay Genie.
Product Name:
Anti-RNase L In Vivo Antibody - Ultra Low Endotoxin
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Purity:
≥98% monomer by analytical SEC ⋅ >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Clone 2E9 recognizes an epitope on human/hamster/primate RNaseL.
Antigen Distribution:
RNase L is highly expressed in the spleen and thymus, followed by prostate, testis, uterus, small intestine, colon, and peripheral blood leukocytes.
Immunogen:
Purified, full-length, recombinant, human RNaseL produced in insect cells.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥98% monomer by analytical SEC ⋅ >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
RNase L antibody, clone 2E9, recognizes the interferon (IFN)-inducible 2-5A-dependent ribonuclease L (RNase L), an endoribonuclease involved in antiviral signaling. It is widely expressed as a latent monomer in most mammalian tissues1. 2’,5’-oligoadenylate synthetase (OAS) is expressed following viral infection and exposure to IFN2. OAS proteins are activated by dsRNA, resulting in the production of 2’,5’-linked oligoadenylates (2-5A), which bind to latent RNase L, inducing dimerization and activation2. RNase L inhibits viral replication by cleaving viral and ribosomal RNA3,4 and inducing apoptosis in virus-infected cells5,6. RNase L is suggested to have antitumor effects, possibly through its pro-apoptotic activity7, and mutations in the RNASEL gene are associated with prostate cancer risk and progression8,9.
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Assay Genie's Purified Functional Antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
